A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
A phase 1/2 trial of F18 FBPA Injection in advanced solid tumours, run by Heron Neutron Medical Corp., now recruiting.
Overview
A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors is a phase 1/2 interventional study registered as NCT07691775 by Heron Neutron Medical Corp., with 30 participants planned, started 2026-05-20 and due to reach its primary completion in 2026-12. Interventions recorded: F18 FBPA Injection.
Similar pages
not linked directly; found by shared links- TrialTest-retest Evaluation of [18F]F-AraG PET
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares PET (positron emission tomography), PET/CT, Fluorine-18 and the tag pipeline.
- TrialInvestigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
- TrialThis Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
- TrialHER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares PET (positron emission tomography), PET/CT and the tag pipeline.
- TrialOpen-Label Study of 18F-mFBG for Imaging Neuroblastoma
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialImaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Shares Fluorine-18 and the tag pipeline.